[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv-related-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv-related-disease":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100370084","phase-2-artesunate-vaginal-inserts-for-the-treatment-of-cervical-intraepithelial-neoplasia-cin23-100370084",false,"NCT04098744","Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2\u002F3)","A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2\u002F3)","ART-CIN_IIB","Inclusion Criteria:\n\n* Adult females age ≥ 25 years\n* Capable of informed consent\n* Any HPV genotype detectable by DNA test\u002FHPV genotyping\n* Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2\u002F3)\n* Women of childbearing potential agree to use birth control through week17 of the study.\n* Weight ≥ 50kg\n\nExclusion Criteria:\n\n* Pregnant and nursing women\n* Active autoimmune disease\n* Taking immunosuppressive medication\n* HIV seropositivity\n* Immunocompromised subjects\n* Evidence of concurrent cervical adenocarcinoma in situ\n* Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects","FEMALE","25 Years","100 Years",{"count":21,"type":22},78,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2\u002F3).",[28,29,30,31,32],"CIN 2\u002F3","HPV Infection","Pre-Cancerous Dysplasia","Cervical Dysplasia","HPV Related Disease",[34,35,36,37,38,39,40,41,42,43,44,45],"treatment study","cancer prevention","non-surgical","HPV related disease","CIN","topical treatment","vaginal inserts","artesunate","artemisinin","non-invasive","high risk HPV","vaginal suppository","RECRUITING","2025-09-29",{"date":49,"type":50},"2025-10-02","ACTUAL",{"date":52,"type":50},"2020-09-09",{"date":54,"type":22},"2026-12-31",{"name":56,"class":57},"Frantz Viral Therapeutics, LLC","INDUSTRY",7]